Full approval is crucial for Novavax to proceed with a $175m partnership deal with Sanofi, set to commence in the 2025-2026 ...

A top FDA official directly intervened in an agency review of Novavax’s Covid-19 vaccine, pausing the approval process to ask for more data on the shot, according to four people familiar with the ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare bleeding disorder.

Dr. Christopher J. Sayed shares insights on the growing emphasis on personalized care for hidradenitis suppurativa.

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results ...

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...

"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are ...

Sanofi: Adagene and Sanofi are collaborating to develop both ... The decrease was due to both a reduction in personnel and in office-related expenses as a result of cost-control measures. Other ...

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201.

Sanofi said it would acquire Bispecific Myeloid Cell Engager, an autoimmune disease treatment, from Dren Bio, for up to $1.9 billion. The French pharmaceutical company on Thursday said it would ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing over $600 million upfront for Dren Bio’s clinical-stage bispecific antibody, with more than $1 billion in ...